BACKGROUND AND OBJECTIVES: 22q11.2 Deletion Syndrome (22q11.2DS) is an important genetic syndrome to cardiologists yet remains under-recognized in adults. There is no evidence-based guideline for genetic testing referrals. Feasibility issues in many jurisdictions preclude testing for 22q11.2 deletions in every congenital cardiac patient. We aimed to determine an optimal combination of extracardiac features that could be clinically helpful in identifying adults with tetralogy of Fallot (TOF) and related conotruncal anomalies at highest risk for 22q11.2DS. METHODS: Adults (n=103) at a congenital cardiac clinic (86 with TOF) had a brief clinical screening assessment and genetic testing for 22q11.2 deletions using standard fluorescence in-situ hybridization; 31 had a 22q11.2 deletion. Discriminant ability (DA), defined as (sensitivity+specificity)/2, was used to measure performance of 18 (17 clinical and one demographic) features in predicting 22q11.2DS (DA>80%=a good screening test). RESULTS: Combining two features was required for a good test: a global impression of 22q11.2DS dysmorphic facies, with either learning difficulties (DA=82.4%) or voice abnormalities such as hypernasality (DA=81.6%). A four-feature combination (suggestive dysmorphic facies, voice abnormalities, learning difficulties and age <30 years) yielded maximal sensitivity (100%) and DA>85% at a cut-off of three features. Neither rates of right aortic arch or cardiac surgery differed between patients with and without 22q11.2 deletions. CONCLUSIONS: Clinicians who consider as few as two extracardiac features readily detectable in a brief clinical encounter could help identify those with 22q11.2DS among adults with congenital heart disease. Diagnosis of 22q11.2DS is important for optimizing management of these complex patients.
BACKGROUND AND OBJECTIVES: 22q11.2 Deletion Syndrome (22q11.2DS) is an important genetic syndrome to cardiologists yet remains under-recognized in adults. There is no evidence-based guideline for genetic testing referrals. Feasibility issues in many jurisdictions preclude testing for 22q11.2 deletions in every congenital cardiac patient. We aimed to determine an optimal combination of extracardiac features that could be clinically helpful in identifying adults with tetralogy of Fallot (TOF) and related conotruncal anomalies at highest risk for 22q11.2DS. METHODS: Adults (n=103) at a congenital cardiac clinic (86 with TOF) had a brief clinical screening assessment and genetic testing for 22q11.2 deletions using standard fluorescence in-situ hybridization; 31 had a 22q11.2 deletion. Discriminant ability (DA), defined as (sensitivity+specificity)/2, was used to measure performance of 18 (17 clinical and one demographic) features in predicting 22q11.2DS (DA>80%=a good screening test). RESULTS: Combining two features was required for a good test: a global impression of 22q11.2DS dysmorphic facies, with either learning difficulties (DA=82.4%) or voice abnormalities such as hypernasality (DA=81.6%). A four-feature combination (suggestive dysmorphic facies, voice abnormalities, learning difficulties and age <30 years) yielded maximal sensitivity (100%) and DA>85% at a cut-off of three features. Neither rates of right aortic arch or cardiac surgery differed between patients with and without 22q11.2 deletions. CONCLUSIONS: Clinicians who consider as few as two extracardiac features readily detectable in a brief clinical encounter could help identify those with 22q11.2DS among adults with congenital heart disease. Diagnosis of 22q11.2DS is important for optimizing management of these complex patients.
Authors: Devra B Becker; Thomas Pilgram; Lynn Marty-Grames; Daniel P Govier; Jeffrey L Marsh; Alex A Kane Journal: Plast Reconstr Surg Date: 2004-11 Impact factor: 4.730
Authors: F Amati; A Mari; M C Digilio; R Mingarelli; B Marino; A Giannotti; G Novelli; B Dallapiccola Journal: Hum Genet Date: 1995-05 Impact factor: 4.132
Authors: D A Driscoll; J Salvin; B Sellinger; M L Budarf; D M McDonald-McGinn; E H Zackai; B S Emanuel Journal: J Med Genet Date: 1993-10 Impact factor: 6.318
Authors: Pieter G Postema; Lukas A J Rammeloo; Raphaele van Litsenburg; Ellen G M Rothuis; Jaroslav Hruda Journal: Int J Cardiol Date: 2007-03-27 Impact factor: 4.164
Authors: A K Ryan; J A Goodship; D I Wilson; N Philip; A Levy; H Seidel; S Schuffenhauer; H Oechsler; B Belohradsky; M Prieur; A Aurias; F L Raymond; J Clayton-Smith; E Hatchwell; C McKeown; F A Beemer; B Dallapiccola; G Novelli; J A Hurst; J Ignatius; A J Green; R M Winter; L Brueton; K Brøndum-Nielsen; P J Scambler Journal: J Med Genet Date: 1997-10 Impact factor: 6.318
Authors: Gregory Costain; Candice K Silversides; Christian R Marshall; Mary Shago; Nicholas Costain; Anne S Bassett Journal: Int J Cardiol Date: 2010-07-03 Impact factor: 4.164
Authors: Anne S Bassett; Gregory Costain; Wai Lun Alan Fung; Kathryn J Russell; Laura Pierce; Ronak Kapadia; Ronald F Carter; Eva W C Chow; Pamela J Forsythe Journal: J Psychiatr Res Date: 2010-11 Impact factor: 4.791
Authors: A S Bassett; E W C Chow; J Husted; K A Hodgkinson; E Oechslin; L Harris; C Silversides Journal: J Med Genet Date: 2009-02-25 Impact factor: 6.318
Authors: Gregory Costain; Anath C Lionel; Daniele Merico; Pamela Forsythe; Kathryn Russell; Chelsea Lowther; Tracy Yuen; Janice Husted; Dimitri J Stavropoulos; Marsha Speevak; Eva W C Chow; Christian R Marshall; Stephen W Scherer; Anne S Bassett Journal: Hum Mol Genet Date: 2013-06-27 Impact factor: 6.150
Authors: Nancy J Butcher; Tim-Rasmus Kiehl; Lili-Naz Hazrati; Eva W C Chow; Ekaterina Rogaeva; Anthony E Lang; Anne S Bassett Journal: JAMA Neurol Date: 2013-11 Impact factor: 18.302
Authors: Nancy J Butcher; Wai Lun Alan Fung; Laura Fitzpatrick; Alina Guna; Danielle M Andrade; Anthony E Lang; Eva W C Chow; Anne S Bassett Journal: Br J Psychiatry Date: 2015-03-05 Impact factor: 9.319
Authors: Sara Piran; Anne S Bassett; Jasmine Grewal; Jodi-Ann Swaby; Chantal Morel; Erwin N Oechslin; Andrew N Redington; Peter P Liu; Candice K Silversides Journal: Am Heart J Date: 2011-01 Impact factor: 4.749